Skip to Content

View Additional Section Content

A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)

For more information on this trial, click the link below.

https://clinicaltrials.gov/ct2/show/NCT03701282

Clinical Trial Categories

  • Leukemia
Contact
Ashley Douglas, RN at 215-481-4429

Location

  • Asplundh Cancer Pavilion
    3941 Commerce Ave.
    Willow Grove, PA 19090

Find a Physician
Search Our Directory

215-481-MEDI
215-481-6334

Schedule a
Test

215-481-EXAM
215-481-3926